NASDAQ:INSM

Insmed - INSM Stock Forecast, Price & News

$17.02

-0.40 (-2.30%)

(As of 03/20/2023 12:00 AM ET)

Add

Compare

Today's Range: $16.96
▼
$17.63
50-Day Range: $17.02
▼
$21.73
52-Week Range: $16.41
▼
$28.94

Volume: 1.28 million shs
Average Volume: 1.35 million shs
Market Capitalization: $2.32 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $43.33

Institutional Ownership

Insmed MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 154.6% Upside
$43.33 Price Target
Short Interest: Bearish
7.64% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.29
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$518,005 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($4.41) to ($3.75) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.69 out of 5 stars

Medical Sector

83rd out of 988 stocks

Pharmaceutical Preparations Industry

24th out of 482 stocks

4.5

Analyst's Opinion

Consensus Rating
Insmed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 11 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $43.33, Insmed has a forecasted upside of 154.6% from its current price of $17.02.
Amount of Analyst Coverage
Insmed has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
7.64% of the outstanding shares of Insmed have been sold short.
Short Interest Ratio / Days to Cover
Insmed has a short interest ratio ("days to cover") of 8.
Change versus previous month
Short interest in Insmed has recently decreased by 2.53%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Insmed does not currently pay a dividend.
Dividend Growth
Insmed does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Insmed has received a 71.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Aminoglycosides", "Clinical research services for physical health", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Insmed is -1.29.

3.1

News and Social Media Coverage

News Sentiment
Insmed has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.35 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Insmed this week, compared to 2 articles on an average week.
Search Interest
9 people have searched for INSM on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.
MarketBeat Follows
3 people have added Insmed to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Insmed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $518,005.00 in company stock.
Percentage Held by Insiders
Only 4.63% of the stock of Insmed is held by insiders.
Percentage Held by Institutions
92.83% of the stock of Insmed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Insmed are expected to grow in the coming year, from ($4.41) to ($3.75) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Insmed is -4.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Insmed is -4.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Insmed has a P/B Ratio of 26.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Insmed (NASDAQ:INSM) Stock

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Receive INSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter.

INSM Stock News Headlines

February 24, 2023 | finance.yahoo.com

Insmed Full Year 2022 Earnings: EPS Misses Expectations

February 23, 2023 | finance.yahoo.com

Insmed (INSM) Reports Q4 Loss, Misses Revenue Estimates

March 20, 2023 | Stansberry Research (Ad)

The gold catalyst we’ve waited for

If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.

February 23, 2023 | finance.yahoo.com

Insmed Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

February 19, 2023 | finance.yahoo.com

Insiders of Insmed Incorporated (NASDAQ:INSM) are up 17% on their US$1.7m purchase after Insmed Incorporated (NASDAQ:INSM) rose 5.0% last week

February 14, 2023 | benzinga.com

Insmed Stock (NASDAQ:INSM), Quotes and News Summary

February 9, 2023 | finance.yahoo.com

Insmed to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, February 23, 2023

February 7, 2023 | finance.yahoo.com

Insmed To Present at the SVB Securities Global Biopharma Conference

March 20, 2023 | Weiss Ratings (Ad)

Urgent Warning

This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …

January 24, 2023 | finance.yahoo.com

Wall Street Analysts Believe Insmed (INSM) Could Rally 98.26%: Here's is How to Trade

January 19, 2023 | finance.yahoo.com

The past five years for Insmed (NASDAQ:INSM) investors has not been profitable

January 16, 2023 | marketwatch.com

Cystic Fibrosis Therapeutics Market Size 2023 with Far-reaching scope to cover all the potential segments selection every stakeholder

January 6, 2023 | finance.yahoo.com

Insmed Provides Business Updates and Near-Term Strategic Outlook at 41st Annual J.P. Morgan Healthcare Conference

January 3, 2023 | finance.yahoo.com

Insmed To Present at the 41st Annual J.P. Morgan Healthcare Conference

December 23, 2022 | finance.yahoo.com

Insmed Incorporated (INSM) Stock Historical Prices & Data - Yahoo Finance

December 10, 2022 | cnbc.com

Bank of America says these stocks have the most 'potential upside' this holiday season

December 8, 2022 | cnbc.com

This biotech stock can jump more than 90%, Barclays says

December 8, 2022 | markets.businessinsider.com

Analyst Ratings for Insmed

November 30, 2022 | finance.yahoo.com

Insmed To Present at the Nasdaq 47th Investor Conference

November 5, 2022 | benzinga.com

Insmed Director Trades Company's Stock

November 5, 2022 | msn.com

Insmed's Return On Capital Employed Overview

November 1, 2022 | finance.yahoo.com

Insmed To Present at Three November Conferences

October 28, 2022 | finance.yahoo.com

Insmed Ranks No. 1 on Science's 2022 Top Biopharma Employers List

October 21, 2022 | seekingalpha.com

Insmed inks financing deals to raise $500M; announces $275 common stock offering

October 19, 2022 | uk.investing.com

Why United Airlines Shares Are Trading Higher? Here Are 43 Stocks Moving In Wednesday's Mid-Day Session By Benzinga - Investing.com UK

October 19, 2022 | seekingalpha.com

INSM stock on watch after financing agreements to raise $500M (NASDAQ:INSM) - Seeking Alpha

October 19, 2022 | finance.yahoo.com

Insmed Announces Strategic Financings Totaling $775 Million

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive INSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter.

INSM Company Calendar

Last Earnings: 10/28/2021
Today: 3/20/2023
Next Earnings (Estimated): 5/04/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:INSM
CUSIP: N/A
CIK: 1104506
Web: www.insmed.com
Phone: 908-977-9900
Fax: 732-438-0381
Employees: 373
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $43.33
High Stock Price Forecast: $53.00
Low Stock Price Forecast: $28.00
Forecasted Upside/Downside: +154.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 11 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.90)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-481,530,000.00
Net Margins: -196.26%
Pretax Margin: -195.69%
Return on Equity: -865.02%
Return on Assets: -39.55%

Debt

Debt-to-Equity Ratio: 13.13
Current Ratio: 6.69
Quick Ratio: 6.33

Sales & Book Value

Annual Sales: $245.36 million
Price / Sales: 9.46
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.65 per share
Price / Book: 26.18

Miscellaneous

Outstanding Shares: 136,400,000
Free Float: 130,089,000
Market Cap: $2.32 billion
Optionable: Optionable
Beta: 1.57

Social Links

Key Executives

Mr. William H. Lewis J.D. (Age 50)
Pres, CEO & Chairman

Mr. Paolo Tombesi (Age 55)
Chief Financial Officer

Ms. Christine A. Pellizzari J.D. (Age 51)
Chief Legal Officer & Corp. Sec.

Mr. Roger Adsett (Age 50)
Chief Commercial Officer

Dr. Paul D. Streck (Age 55)
Advisor

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

INSM Stock - Frequently Asked Questions

Should I buy or sell Insmed stock right now?: 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" INSM shares.
View INSM analyst ratings or view top-rated stocks.
What is Insmed's stock price forecast for 2023?: 11 Wall Street research analysts have issued 12-month price targets for Insmed's shares. Their INSM share price forecasts range from $28.00 to $53.00. On average, they anticipate the company's share price to reach $43.33 in the next twelve months. This suggests a possible upside of 154.6% from the stock's current price.
View analysts price targets for INSM or view top-rated stocks among Wall Street analysts.
How have INSM shares performed in 2023?: Insmed's stock was trading at $19.98 at the beginning of the year. Since then, INSM stock has decreased by 14.8% and is now trading at $17.02.
View the best growth stocks for 2023 here.
When is Insmed's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our INSM earnings forecast.
How were Insmed's earnings last quarter?: Insmed Incorporated (NASDAQ:INSM) issued its earnings results on Thursday, October, 28th. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.83) by $0.13. The biopharmaceutical company had revenue of $46.80 million for the quarter, compared to analysts' expectations of $49.23 million. Insmed had a negative trailing twelve-month return on equity of 865.02% and a negative net margin of 196.26%. Insmed's revenue was up 6.8% on a year-over-year basis. During the same period in the prior year, the company posted ($0.63) EPS.
What ETFs hold Insmed's stock?: ETFs with the largest weight of Insmed (NASDAQ:INSM) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3X Shares (LABU), Principal Healthcare Innovators ETF (BTEC), iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Russell 2000 Growth ETF (IWO) and JPMorgan BetaBuilders U.S. Small Cap Equity ETF (BBSC).
What is Will Lewis' approval rating as Insmed's CEO?: 14 employees have rated Insmed Chief Executive Officer Will Lewis on Glassdoor.com. Will Lewis has an approval rating of 78% among the company's employees.

What other stocks do shareholders of Insmed own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include Gilead Sciences (gild), AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA) and Geron (GERN).
What is Insmed's stock symbol?: Insmed trades on the NASDAQ under the ticker symbol "INSM."
Who are Insmed's major shareholders?: Insmed's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (7.36%), T. Rowe Price Investment Management Inc. (6.18%), William Blair Investment Management LLC (2.50%), Alliancebernstein L.P. (1.92%), Geode Capital Management LLC (1.84%) and Norges Bank (0.99%). Insiders that own company stock include Alfred Altomari, Christine A Pellizzari, David R Brennan, John Drayton Wise, John Soriano, Martina MD Flammer, Melvin Md Sharoky, Michael Alexander Smith, Orlov S Nicole Schaeffer, Roger Adsett, Sara Bonstein and William Lewis.
View institutional ownership trends.
How do I buy shares of Insmed?: Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Insmed's stock price today?: One share of INSM stock can currently be purchased for approximately $17.02.
How much money does Insmed make?: Insmed (NASDAQ:INSM) has a market capitalization of $2.32 billion and generates $245.36 million in revenue each year. The biopharmaceutical company earns $-481,530,000.00 in net income (profit) each year or ($3.90) on an earnings per share basis.
How many employees does Insmed have?: The company employs 373 workers across the globe.
How can I contact Insmed?: Insmed's mailing address is 700 US Highway 202/206, Bridgewater NJ, 08807. The official website for the company is www.insmed.com. The biopharmaceutical company can be reached via phone at 908-977-9900, via email at investor.relations@insmed.com, or via fax at 732-438-0381.

This page (NASDAQ:INSM) was last updated on 3/20/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Insmed - INSM Stock Forecast, Price & News

Insmed MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Insmed (NASDAQ:INSM) Stock

INSM Stock News Headlines

INSM Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

INSM Stock - Frequently Asked Questions

Overall MarketRank^™